Neoadjuvant therapy 1

Phase 2Small molecule

TTang-Du Hospital

Neoadjuvant therapy 1 is one of 57 small molecule programs targeting PD-1 Inhibitor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PD-1 InhibitorActive, not recruiting

Gastroesophageal Junction CarcinomaNot yet recruiting

Non-Small Cell Lung CancerRecruiting

Pleural MesotheliomaRecruiting

PD-1 InhibitorPhase 2

Active, not recruiting

Gastroesophageal Junction CarcinomaPreclinical

Not yet recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Pleural MesotheliomaPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Phase 3

6 2

Sigvotatug Vedotin

Pfizer

Phase 3

1 3

Neoadjuvant therapy 1

TTang-Du Hospital

Phase 2

1 4

BPI-7711

BBeta Pharma Shanghai

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

PD-1 Inhibitor

NCT05400070

Q4 2027

N/ANot yet recruiting

Gastroesophageal Junction Carcinoma

NCT07092449

Q3 2029

Phase 1/2Recruiting

Pleural Mesothelioma

NCT07121374

Clinical

Trials by Indication[1]

PD-1 Inhibitor1 trial

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Active, not recruiting·TTang-Du Hospital·Phase 2·NCT05400070·45 enrolled

Pleural Mesothelioma1 trial

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

Recruiting·UUniversity Hospital, Antwerp·Phase 1/2·NCT07121374·37 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Recruiting·SSun Yat-sen University·Phase 2·NCT05468242·116 enrolled

Gastroesophageal Junction Carcinoma1 trial

Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma

Not yet recruiting·TTang-Du Hospital·N/A·NCT07092449·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Neoadjuvant therapy 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant therapy 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant therapy 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTang-Du Hospital

Neoadjuvant therapy 1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2029

Trials by Indication[1]

PD-1 Inhibitor1 trial

Pleural Mesothelioma1 trial

Non-Small Cell Lung Cancer1 trial

Gastroesophageal Junction Carcinoma1 trial

References

Drug Info

Quick Facts

Related News